RCSI and Head Diagnostics collaborate to revolutionize multiple sclerosis assessment

RCSI has partnered with Head Diagnostics (Dublin, Ireland) on a clinical study to enhance the assessment and monitoring of Multiple Sclerosis (MS) through innovative technology. The study, launched to coincide with World MS Day, will explore the use of novel digital biomarkers to monitor disease, with the aim of providing greater objectivity in assessing the condition.

MS is a complex neurological disorder that affects millions of people worldwide. ​The current methods of assessing disease progression and treatment effect for MS patients are limited and often subjective. This new collaboration aims to address this issue by exploring the potential of non-invasive digital biomarkers, including a little-known tremor of the eye, and measures of a person's manner of walking, to provide accurate and real-time data on disease activity.

​Central to the study is Head Diagnostics' innovative iTremor One device, a handheld medical device that gives a rapid and non-invasive measure of ocular microtremor (OMT), a high frequency involuntary fixational eye movement that is believed to reflect activity in the brainstem. Previous studies have found that OMT changes in people with MS, as well as other neurological conditions, although the traditional approach to measuring this has been particularly invasive, limiting research. Combining this measure with gait analysis offers the potential to provide more comprehensive, accurate and real-time data on disease activity.

This observational study based out of Beaumont Hospital is designed to evaluate the utility of OMT and gait in monitoring MS, enrolling 120 participants including those with and without a diagnosis of MS, and assessing them regularly over a 12-month period.

Exploring the potential of measuring patients' microtremors of the eye and their gait as measures of MS progression offers a promising new direction in our management approach. The treatment options for MS patients have advanced dramatically in recent decades but the outcome measures we use in clinical practice do not capture all aspects of the disease, in particular early disease progression. This study marks a significant step in exploration of more precise and robust monitoring of MS, which is crucial for effective management and treatment."

Dr. Lisa Costelloe, Honorary Clinical Senior Lecturer at RCSI, Consultant Neurologist at Beaumont Hospital, and Study Co-Principal Investigator

Dr Rob Argent, Lecturer in Digital and Connected Health in RCSI's School of Pharmacy and Biomolecular Sciences and study Co-Principal Investigator noted the importance of this research saying: "This study presents a unique opportunity to develop digital measures that can provide a more convenient, comprehensive, and objective measure of MS. By leveraging digital health technologies, we seek to support assessment, enhance disease monitoring, and contribute to the advancement of precision medicine in MS."

"In combining our innovative iTremor One device with RCSI's research expertise, we aim to revolutionise the way MS is assessed and monitored," said David van Zuydam, Head Diagnostics' CEO. "This study supports our mission to provide objective and real-time disease management tools for neurological diseases and impairments."

This study is supported by the Enterprise Ireland Innovation Partnership Programme, which provides funding and support for collaborative research projects between industry and academic institutions in Ireland.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breathing New Life into Diagnostics: Plasmion's SICRIT® Technology